Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | DOI[10.1038/nbt.2488] | |||
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | prostate gland |
PMID[19212411] |
||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 1080 | nM | 17302398 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC322594 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC320249 |
0.9881 | High Similarity | NPC324390 |
0.9655 | High Similarity | NPC283698 |
0.9655 | High Similarity | NPC73765 |
0.954 | High Similarity | NPC36985 |
0.954 | High Similarity | NPC17892 |
0.9048 | High Similarity | NPC106780 |
0.8889 | High Similarity | NPC324516 |
0.8889 | High Similarity | NPC318166 |
0.8876 | High Similarity | NPC327344 |
0.8791 | High Similarity | NPC317639 |
0.8736 | High Similarity | NPC89051 |
0.8736 | High Similarity | NPC43246 |
0.866 | High Similarity | NPC329277 |
0.8485 | Intermediate Similarity | NPC155087 |
0.8485 | Intermediate Similarity | NPC149843 |
0.809 | Intermediate Similarity | NPC112842 |
0.809 | Intermediate Similarity | NPC71339 |
0.8085 | Intermediate Similarity | NPC329384 |
0.8043 | Intermediate Similarity | NPC315063 |
0.8 | Intermediate Similarity | NPC325723 |
0.7917 | Intermediate Similarity | NPC120887 |
0.7835 | Intermediate Similarity | NPC328779 |
0.7826 | Intermediate Similarity | NPC210456 |
0.7826 | Intermediate Similarity | NPC163352 |
0.7812 | Intermediate Similarity | NPC226769 |
0.7812 | Intermediate Similarity | NPC6166 |
0.7812 | Intermediate Similarity | NPC280946 |
0.7677 | Intermediate Similarity | NPC328914 |
0.766 | Intermediate Similarity | NPC171116 |
0.7551 | Intermediate Similarity | NPC90240 |
0.7368 | Intermediate Similarity | NPC284651 |
0.7312 | Intermediate Similarity | NPC229249 |
0.7303 | Intermediate Similarity | NPC329077 |
0.7222 | Intermediate Similarity | NPC325902 |
0.7083 | Intermediate Similarity | NPC190334 |
0.7083 | Intermediate Similarity | NPC62927 |
0.6737 | Remote Similarity | NPC319753 |
0.6337 | Remote Similarity | NPC328806 |
0.6311 | Remote Similarity | NPC315058 |
0.616 | Remote Similarity | NPC313962 |
0.6064 | Remote Similarity | NPC315806 |
0.5983 | Remote Similarity | NPC478024 |
0.5962 | Remote Similarity | NPC109188 |
0.5887 | Remote Similarity | NPC325750 |
0.5846 | Remote Similarity | NPC318142 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC322594 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9655 | High Similarity | NPD9639 | Clinical (unspecified phase) |
0.8837 | High Similarity | NPD9557 | Clinical (unspecified phase) |
0.8736 | High Similarity | NPD9581 | Clinical (unspecified phase) |
0.8736 | High Similarity | NPD9580 | Clinical (unspecified phase) |
0.866 | High Similarity | NPD3129 | Phase 3 |
0.8557 | High Similarity | NPD3128 | Phase 3 |
0.8372 | Intermediate Similarity | NPD9556 | Approved |
0.8316 | Intermediate Similarity | NPD5789 | Clinical (unspecified phase) |
0.8276 | Intermediate Similarity | NPD9561 | Approved |
0.8276 | Intermediate Similarity | NPD9560 | Approved |
0.8182 | Intermediate Similarity | NPD9546 | Phase 2 |
0.8152 | Intermediate Similarity | NPD9565 | Discontinued |
0.809 | Intermediate Similarity | NPD9533 | Phase 2 |
0.809 | Intermediate Similarity | NPD280 | Approved |
0.7925 | Intermediate Similarity | NPD3139 | Phase 3 |
0.7912 | Intermediate Similarity | NPD9562 | Discovery |
0.7912 | Intermediate Similarity | NPD240 | Phase 3 |
0.7912 | Intermediate Similarity | NPD170 | Approved |
0.783 | Intermediate Similarity | NPD3138 | Phase 3 |
0.7789 | Intermediate Similarity | NPD1686 | Approved |
0.7778 | Intermediate Similarity | NPD9529 | Phase 1 |
0.7778 | Intermediate Similarity | NPD9559 | Phase 1 |
0.7753 | Intermediate Similarity | NPD9558 | Phase 3 |
0.7708 | Intermediate Similarity | NPD501 | Phase 1 |
0.7692 | Intermediate Similarity | NPD239 | Phase 2 |
0.7692 | Intermediate Similarity | NPD238 | Clinical (unspecified phase) |
0.7677 | Intermediate Similarity | NPD1455 | Phase 3 |
0.7677 | Intermediate Similarity | NPD1454 | Phase 3 |
0.766 | Intermediate Similarity | NPD841 | Approved |
0.766 | Intermediate Similarity | NPD755 | Phase 3 |
0.7551 | Intermediate Similarity | NPD762 | Discontinued |
0.7475 | Intermediate Similarity | NPD502 | Approved |
0.7447 | Intermediate Similarity | NPD241 | Discontinued |
0.732 | Intermediate Similarity | NPD251 | Approved |
0.7315 | Intermediate Similarity | NPD7914 | Suspended |
0.7312 | Intermediate Similarity | NPD9601 | Approved |
0.7143 | Intermediate Similarity | NPD6946 | Approved |
0.7083 | Intermediate Similarity | NPD9602 | Phase 3 |
0.7083 | Intermediate Similarity | NPD9604 | Approved |
0.7083 | Intermediate Similarity | NPD9603 | Phase 3 |
0.701 | Intermediate Similarity | NPD9554 | Approved |
0.701 | Intermediate Similarity | NPD9553 | Approved |
0.6989 | Remote Similarity | NPD9600 | Approved |
0.6952 | Remote Similarity | NPD1061 | Clinical (unspecified phase) |
0.6907 | Remote Similarity | NPD1760 | Approved |
0.6869 | Remote Similarity | NPD267 | Discontinued |
0.6842 | Remote Similarity | NPD9572 | Clinical (unspecified phase) |
0.6842 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.6837 | Remote Similarity | NPD301 | Discontinued |
0.68 | Remote Similarity | NPD9585 | Discontinued |
0.68 | Remote Similarity | NPD6943 | Clinical (unspecified phase) |
0.6737 | Remote Similarity | NPD9573 | Phase 2 |
0.6731 | Remote Similarity | NPD192 | Phase 2 |
0.6667 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD215 | Discontinued |
0.6609 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.6606 | Remote Similarity | NPD1385 | Discontinued |
0.6562 | Remote Similarity | NPD7761 | Suspended |
0.6542 | Remote Similarity | NPD7651 | Approved |
0.6538 | Remote Similarity | NPD514 | Clinical (unspecified phase) |
0.6535 | Remote Similarity | NPD500 | Discontinued |
0.6531 | Remote Similarity | NPD9555 | Phase 2 |
0.6512 | Remote Similarity | NPD9503 | Approved |
0.6512 | Remote Similarity | NPD9504 | Approved |
0.6422 | Remote Similarity | NPD2633 | Phase 1 |
0.6408 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6224 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6195 | Remote Similarity | NPD6693 | Phase 3 |
0.6161 | Remote Similarity | NPD1428 | Phase 2 |
0.6132 | Remote Similarity | NPD6948 | Phase 3 |
0.6129 | Remote Similarity | NPD9405 | Approved |
0.6111 | Remote Similarity | NPD3121 | Phase 2 |
0.61 | Remote Similarity | NPD205 | Approved |
0.6082 | Remote Similarity | NPD9427 | Approved |
0.6064 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.6055 | Remote Similarity | NPD765 | Discontinued |
0.602 | Remote Similarity | NPD9429 | Discontinued |
0.5982 | Remote Similarity | NPD4743 | Phase 2 |
0.5962 | Remote Similarity | NPD1331 | Approved |
0.5948 | Remote Similarity | NPD1804 | Phase 2 |
0.5948 | Remote Similarity | NPD1805 | Phase 2 |
0.5938 | Remote Similarity | NPD9407 | Approved |
0.5862 | Remote Similarity | NPD284 | Phase 1 |
0.5849 | Remote Similarity | NPD285 | Discontinued |
0.5758 | Remote Similarity | NPD9403 | Discontinued |
0.5714 | Remote Similarity | NPD723 | Phase 2 |
0.5656 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.5656 | Remote Similarity | NPD6935 | Phase 3 |
0.561 | Remote Similarity | NPD6918 | Phase 1 |
PubChem CID   | 65070 |
ChEMBL   | CHEMBL374361 |
ZINC   |
Molecular Weight:   | 467.97 |
ALogP:   | -2.8192 |
MLogP:   | 0.36 |
XLogP:   | -5.297 |
# Rotatable Bonds:   | 14 |
Polar Surface Area:   | 271.61 |
# H-Bond Aceptor:   | 16 |
# H-Bond Donor:   | 6 |
# Rings:   | 2 |
# Heavy Atoms:   | 28 |